Cited by 244Inflammasome and immune disordersImmune Response and InflammationIL-33, ST2, and ILC Pathways

The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.

Inflammasome Priming in Sterile Inflammatory Disease

Abstract

The inflammasome is a cytoplasmic protein complex that processes interleukins (IL)-1β and IL-18, and drives a form of cell death known as pyroptosis. Oligomerization of this complex is actually the second step of activation, and a priming step must occur first. This involves transcriptional upregulation of pro-IL-1β, inflammasome sensor NLRP3, or the non-canonical inflammasome sensor caspase-11. An additional aspect of priming is the post-translational modification of particular inflammasome constituents. Priming is typically accomplished in vitro using a microbial Toll-like receptor (TLR) ligand. However, it is now clear that inflammasomes are activated during the progression of sterile inflammatory diseases such as atherosclerosis, metabolic disease, and neuroinflammatory disorders. Therefore, it is time to consider the endogenous factors and mechanisms that may prime the inflammasome in these conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmed.2016.12.007

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Flagged first, then by citations

Research works printed but not linked: 4

  1. Panchanathan, 2016, Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation, Oncotarget, 7, 28183, 10.18632/oncotarget.8594 · DOI
  2. Masters, 2010, Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes, Nat. Immunol., 11, 897, 10.1038/ni.1935 · DOI · Paper page
  3. Duewell, 2010, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature, 464, 1357, 10.1038/nature08938 · DOI · Paper page
  4. Juliana, 2012, Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation, J. Biol. Chem., 287, 36617, 10.1074/jbc.M112.407130 · DOI

Cited by

Sorted by citations

See all 244

Metadata

Authors
Patel, M. N., Carroll, R. G., Galván-Peña, S., Mills, E. L., Olden, R., Triantafilou, M., Wolf, A. I., Bryant, C. E., Triantafilou, K., & Masters, S. L.
Affiliations
  • GlaxoSmithKline (United Kingdom) (GB)
  • GlaxoSmithKline (United States) (US)
  • The University of Melbourne (AU)
Corresponding author
Masters, Seth L.
Venue
Trends in Molecular Medicine
Publisher
Elsevier BV
Published
2017-02
Volume
23
Issue
2
Pages
165-180
ISSN
1471-4914 (ISSN-L)
OpenAlex
W2572287198
Cited by
241
References
153
Citations by year
2026: 12 · 2025: 17 · 2024: 15 · 2023: 24 · 2022: 29 · 2021: 25 · 2020: 37 · 2019: 31 · 2018: 33 · 2017: 17
FWCI
3.02
Type
journal article
Language
en
Open access
closed
Locations
  • Trends in Molecular Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders
Wellcome Trust
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
Keywords
inflammasome priming, sterile inflammation, NLRP3 inflammasome, caspase-11, IL-1β processing, IL-18, pyroptosis, post-translational modification, atherosclerosis, metabolic disorders, neuroinflammation, Toll-like receptor ligands
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Alzheimer Disease, Animals, Humans, Immunity, Innate, Inflammation, Metabolic Diseases, Obesity, Neuroimmunomodulation, Atherosclerosis, Toll-Like Receptors, Interleukin-1beta, Hereditary Autoinflammatory Diseases, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review